image
Healthcare - Biotechnology - NASDAQ - US
$ 0.105
-1.73 %
$ 6.92 M
Market Cap
-0.07
P/E
CASH FLOW STATEMENT
-70 M OPERATING CASH FLOW
-10.59%
80.3 M INVESTING CASH FLOW
738.15%
8.53 M FINANCING CASH FLOW
-87.01%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lyra Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20192019202020202021202120222022202320232024202420252025
Net Income -93.4 M
Depreciation & Amortization 471 K
Capital Expenditures -2.34 M
Stock-Based Compensation 6.72 M
Change in Working Capital -6.35 M
Others 18.1 M
Free Cash Flow -72.3 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018
OPERATING CASH FLOW
Net Income (93.4) (62.7) (55.3) (43.5) (22.1) (16.3) (6.0)
Depreciation & Amortization 0.5 0.3 1.1 1.0 95 K 27 K 82 K
Deferred Income Tax 0 0 0 (2.4) 0 0 0
Stock Based Compensation 6.7 5.9 5.4 2.8 1.8 0.2 0.4
Other Operating Activities 22.6 (1.9) 0.8 2.4 45 K 0.2 (1.2)
Change in Working Capital (6.3) (4.9) 4.6 13.9 (0.9) 2.1 79 K
Cash From Operations (70.0) (63.3) (43.4) (25.8) (21.1) (13.8) (6.6)
INVESTING CASH FLOW
Capital Expenditures (2.3) (1.0) (0.2) (3.4) (1.8) (0.2) 37 K
Other Items 82.6 (11.5) (64.8) 0 0 0 0
Cash From Investing Activities 80.3 (12.6) (65.0) (3.4) (1.8) (0.2) 37 K
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0
Total Debt Repaid 0 0 0 0 0 0 0.5
Dividends Paid 0 0 0 0 0 0 0
Other Financing Activities (0.3) (3.6) (4.2) 0.4 27.8 (0.1) 57.7
Cash From Financing Activities 8.5 65.7 96.3 0.4 87.7 (0.1) 29.2
CHANGE IN CASH
Net Change In Cash 18.8 (10.2) (12.1) (28.8) 64.8 (14.1) 22.5
FREE CASH FLOW
Free Cash Flow (72.3) (64.4) (43.5) (29.2) (22.9) (14.0) (6.7)